Lorenzo Fornaro

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Pembrolizumab Versus Paclitaxel, Gastrointestinal Oncology, Medicine +7

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

Gianluca Masi, Fotios Loupakis, Lisa Salvatore et al. · The Lancet Oncology · 2010 · 240 citations

Oncology, Gastrointestinal Oncology, Medicine +9

Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases

Gianluca Masi, Fotios Loupakis, Luca Emanuele Pollina et al. · Annals of Surgery · 2009 · 234 citations

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Miao‐Zhen Qiu, Do‐Youn Oh, Ken Kato et al. · BMJ · 2024 · 195 citations · Full text

Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy

Vincenzo Catalano, Fotios Loupakis, Francesco Graziano et al. · British Journal of Cancer · 2009 · 191 citations · Full text